Third‐generation EGFR‐TKIs significantly improved mPFS in T790M‐negative patients with EGFR‐mutated advanced NSCLC and resistant to first‐line treatment with first‐ or second‐generation EGFR‐TKIs. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.